Reborna Biosciences, Inc.
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
Reborna is a next-generation biotech pioneering RNA-targeted small molecule therapeutics to unlock disease mechanisms beyond the reach of conventional drug discovery. We are seeking strategic partnerships and financing to advance our programs into the clinic.
Our core technology, RNA Insight, enables screening against full-length mRNA and mini-genes—a fundamentally different approach from conventional fragment-based methods. To our knowledge, we are the only company that has successfully applied full-length RNA to small-molecule screening to generate a robust pipeline, enabling highly selective and functionally relevant drug candidates.
Our pipeline spans from target identification to preclinical development, focusing on splicing modulators and gene expression enhancers across CNS diseases, cancer and rare diseases.
Company HQ City:
Fujisawa
Company HQ State:
Kanagawa
Company HQ Country:
Japan
Year Founded:
2018
Lead Product in Development:
RBS-387
CEO
Dr. Koji Fuji
Development Phase of Lead Product
Discovery
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
2027
What is your next catalyst (value inflection) update?
Safety Tox
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}